TABLE 1.
Baseline characteristics of CIF-positive and CIF-negative patientsa
| Characteristic | CIF positive (n = 101) | CIF negative (n = 110) | P value |
|---|---|---|---|
| Mean age (yr) | 33.2 | 32.4 | 0.60 |
| Female sex (no. [%]) | 49 (48.5) | 58 (52.7) | 0.50 |
| F508del/F508del (no. [%]) | 50 (49.5) | 63 (57.3) | 0.15 |
| FEV1 (% predicted [mean ± SD]) | 62.3 ± 23.3 | 66.1 ± 23.2 | 0.23 |
| Pancreatic insufficiency (no. [%]) | 88 (87.1) | 93 (84.6) | 0.70 |
| Pseudomonas colonization (no. [%]) | 89 (88.1) | 88 (80.0) | 0.14 |
| Treatment (no. [%]) | |||
| Inhaled antibioticb | 82 (81.2) | 76 (69.1) | 0.05 |
| Chronic oral antibioticc | 28 (27.7) | 15 (13.6) | 0.01 |
| Azithromycin | 71 (70.3) | 76 (69.1) | 0.93 |
| Antifungald | 7 (6.9) | 7 (6.4) | 0.88 |
a
CIF, clinically important fungi defined as Aspergillus, Scedosporium, Trichosporon, and Exophiala species.
b
Tobramycin powder/solution, aztreonam, colistin, or ceftazidime.
c
Sulfamethoxazole/trimethoprim, minocycline, doxycycline, or linezolid.
d
Itraconazole, voriconazole, or posaconazole.